Aptar Digital Health acquires Healint to broaden neurology portfolio
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
Minzoya Tablets are indicated for use by females of reproductive potential to prevent pregnancy
The restructuring aims to create synergies across the business and strengthen capital structure
Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination
It is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S.
Subscribe To Our Newsletter & Stay Updated